The Effects of Reinforced Walking Exercise on Dyspnea-fatigue Symptoms, Daily Activities, Walking Ability, and Health related Quality of Life in Heart Failure Patients

Hyekyung Jin; Haejung Lee

doi:10.7469/kjan.2016.28.3.266

Articles

Page Path

Original Article

The Effects of Reinforced Walking Exercise on Dyspnea-fatigue Symptoms, Daily Activities, Walking Ability, and Health related Quality of Life in Heart Failure Patients

Hyekyung Jin, Haejung Lee

Korean Journal of Adult Nursing 2016;28(3):266-278.
Published online: June 30, 2016

DOI: https://doi.org/10.7469/kjan.2016.28.3.266

College of Nursing, Pusan National University, Yangsan, Korea

Corresponding author: Lee, Haejung College of Nursing, Pusan National University, 49 Busandaehak-ro, Mulgeum-eup, Yangsan 50612, Korea. Tel: +82-51-510-8344, Fax: +82-51-510-8308, E-mail: haejung@pusan.ac.kr

• Received: March 1, 2016 • Accepted: June 22, 2016

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

18 Views
0 Download
5 Crossref
4 Scopus

prev next

Full Article

Download PDF

Abstract
REFERENCES

Abstract

Purpose
The purpose of this study was to identify the effects of reinforced walking exercise on dyspnea-fatigue symptoms, daily activities, walking ability and health related quality of life (HRQoL) in heart failure patients.
Methods
This study used a randomized controlled trial design. The participants (experimental group=16, control group=25) were recruited from a university hospital in Kyeong-nam area. Data were collected from March to September, 2015. The reinforced walking exercise included goal setting and feedback (telephone and text message) provided for 12 weeks. Dyspnea-Fatigue Index, Korean Activity Scale/Index (KASI), six-minute walking distance (6MWD) and HRQoL were measured. Data were analyzed using descriptive statistics, t-test, Fisher's exact test, χ² test, and Kolmogrove-Smirnov test.
Results
Prior to the intervention there were no differences in the research variables between two groups. The exercise compliance in the experimental group was 100% (walking for 50 minutes per day, 5 times per week). The experimental group had improved dyspnea-fatigue symptoms (t=8.63, p<.001), daily activities (t=-4.92, p<.001), longer 6MWD (t=-5.66, p<.001), and increased HRQoL (t=-9.05, p<.001) compared to the control group.
Conclusion
The reinforced walking exercise could be a cost-effective intervention in heart failure patient, which could enhance patients’ outcomes, such as improving dyspnea-fatigue symptoms, daily activities, walking ability, and quality of life.
Key Words: Heart failure; Walking; Quality of life

Figure 1.

Flow chart of data collection.

Table 1.

Reinforced Walking Exercise Program

Categories	Contents	Time
1) Preparation	(1) Perform physical assessment (Vital sign & SpO2)	10 min
	(2) Instruct how to use pedometer: Mode & Reset
	(3) Offer exercise diary & teach how to use the diary: Recording number of steps, duration of exercise, weekly frequency, heart rate, and dyspnea/fatigue borg scale
2) Goal setting	(1) Perform walking exercise using the pedometer	5 min
	(2) Start from 5,000 steps & 10% increase/week
	Start from 1 day/week → 5 days/week
	1st week: 5,000 steps & 1 day/week
	2nd week: 6,000 steps & 2 days/week
	3rd week: 7,000 steps & 3 days/week
	4th week: 8,000 steps & 4 days/week
	5th week: 9,000 steps & 5 days/week
	6th week: 10,000 steps & 5 days/week
	7~12th week: maintain 10,000↑steps & 5 days/week
	(3) Maintain symptom of dyspnea/fatigue based on borg scale 12~13 point, maximum heart rate 60~70%
3) Feedback	(1) Check pedometer data and incomplete data	5 min
	(2) Mutually set a weekly goal of walking.
	(3) Reinforce maintenance of walking exercise
	→ through telephone call:
	1st~6th week=once a week
	7~12th week=every other week
	→ by text message: 2 days/week

Table 2.

Characteristics and Homogeneity Test between Control and Experimental Groups (N=41)

Characteristics		Categories	Total	Control (n=25)	Exp. (n=16)	x² or t (p)
Characteristics		Categories	n (%) or M±SD	D n (%) or M±SD	n (%) or M±SD	x² or t (p)
Age (year) (range 40~77)		＜65	30 (73.2)	17 (68.0)	13 (81.3)	0.87 (.287)^§
		≥65	11 (26.8)	8 (32.0)	3 (18.8)	-0.86 (.393)
			58.02±12.04	56.72±14.38	60.06±6.97
Gender		Male	30 (73.2)	17 (68.0)	13 (81.3)	0.87 (.478)^§
Gender		Female	11 (26.8)	8 (32.0)	3 (18.8)
Spouse		No	2 (4.9)	0 (0.0)	2 (12.5)	3.29 (.146)^§
Spouse		Yes	39 (95.1)	25 (100.0)	14 (87.5)
Level of education		≤Junior high school	9 (22.0)	7 (28.0)	2 (12.5)	6.61 (.085)
		High school	13 (31.7)	5 (20.0)	8 (50.0)
		≥College	19 (46.3)	13 (52.0)	6 (37.5)
Regular exercise		No	41 (100.0)	25 (100.0)	16 (100.0)
Monthly household income (10,000 won)		＜100	4 (9.8)	2 (8.0)	2 (12.5)	0.32 (.854)
		100~199	7 (17.1)	4 (16.0)	3 (18.8)
		≥200	30 (73.2)	19 (76.0)	11 (68.8)
Left ventricular ejection fraction (%)			31.15±6.92	31.88±6.98	30.00±6.88	0.85 (.403)
NYHA class		II	36 (87.8)	22 (88.8)	14 (87.5)	0.01 (＞.999)^§
NYHA class		III	5 (12.2)	3 (12.0)	2 (12.5)
Comorbidity		No	16 (39.0)	11 (44.0)	5 (31.3)	0.67 (.519)^§
		Yes^†	25 (61.0)	14 (56.0)	11 (68.8)
		Hypertension	25 (100.0)	14 (56.0)	11 (44.0)
		Diabetes mellitus	6 (24.0)	2 (8.0)	4 (16.0)
		Etc.^‡	7 (28.0)	3 (12.0)	4 (16.0)
Medication	Beta-blocker	Yes	35 (85.4)	21 (84.0)	14 (87.5)	0.10 (＞.999)^§
	Beta-blocker	No	6 (14.6)	4 (16.0)	2 (12.5)
	ACE inhibitor	Yes	29 (70.7)	17 (68.0)	12 (75.0)	0.23 (.734)^§
	ACE inhibitor	No	12 (29.3)	8 (32.0)	4 (25.0)
	Diuretics	Yes	31 (75.6)	19 (76.0)	12 (75.0)	0.01 (＞.999)^§
	Diuretics	No	10 (24.4)	6 (24.0)	4 (25.0)
Physical activity (MET-minutes/week)		Inactive	26 (63.4)	18 (72.0)	8 (50.0)	3.11 (.211)
		Minimally active	11 (26.8)	6 (24.0)	3 (31.3)
		HEPA	4 (9.8)	1 (2.4)	3 (18.8)

Exp.=experimental group; NYHA=New York Heart Association; HEPA=Health enhancing physical activity;

^†Multiple responses;

^‡Liver disease, osteoporosis, angina pectoris, pulmonary disease;

^§Fisher's exact test.

Table 3.

Levels of Dyspnea-fatigue Symptoms, Daily Activities, Walking Ability and Health related QoL and Homogeneity Test (N=41)

Characteristics	Total	Cont. (n=25)		Exp. (n=16)		t (p)
Characteristics	M±SD	M±SD	Z^† (p)	M±SD	Z^† (p)	t (p)
Dyspnea-fatigue symptoms	5.90±1.88	6.20±1.78	0.967 (.307)	5.44±2.00	.943 (.336)	1.28 (.210)
Daily activities (KASI)	34.76±11.75	35.02±11.57	0.646 (.798)	34.35±12.40	.817 (.517)	0.18 (.861)
Walking ability (6MWD; m)	337.32±71.03	339.20±79.11	1.019 (.251)	334.38±58.53	.388 (.998)	0.21 (.835)
HRQoL	69.80±11.69	72.54±11.77	1.052 (.219)	65.53±10.53	.823 (.508)	1.94 (.060)

Exp.=experimental group; Cont.=control group; KASI=Korean Activity Scale/Index; 6MWD=Six-minute walk distance; HRQoL=Health related quality of life.

^†Kolmogorov-Smirnove test.

Table 4.

Walking Compliance and Levels of Physical Activity in Experimental Group (N=16)

Characteristics	Pretest	Posttest	t (p)
Characteristics	n (%) or M±SD	n (%) or M±SD	t (p)
Walking compliance (MET-minute/week)^†
＜825	15 (93.8)	0 (0.0)
≥825	1 (6.3)	16 (100.0)
Physical activity^‡	2110.50±1693.79	3611.25±2513.51	3.45 (.041)
Inactive	8 (50.0)	0 (0.0)
Minimally active	5 (31.3)	12 (75.0)
HEPA	3 (18.8)	4 (25.0)

MET=metabolic equivalent task; HEPA=health enhancing physical activity;

^†Walking 3.3 MET × 50 min/day × 5 times/week=825 MET-min/week;

^‡International Physical Activity Questionnaire scoring protocol (MET-min/week).

Table 5.

Effects of Reinforced Walking Exercise Program on Patients Outcomes (N=41)

Variables	Groups	Pretest	Posttest	t (p)^†	Mean differences	t (p)
Variables	Groups	M±SD	M±SD	t (p)^†	Mean differences	t (p)
Global perceived improvement in dyspnea-fatigue	Cont. (n=25)	-	4.08±0.57			8.63
Global perceived improvement in dyspnea-fatigue	Exp. (n=16)	-	2.56±0.51			(＜.001)^‡
Daily activities (KASI)	Cont. (n=25)	35.02±11.57	35.38±12.00	0.60 (.553)	0.36±3.02	-4.92 (＜.001)
Daily activities (KASI)	Exp. (n=16)	34.35±12.40	39.80±13.03	6.16 (＜.001)	5.45±3.53
Walking ability (6MWD, m)	Cont. (n=25)	339.20±79.11	349.60±78.87	-1.64 (.114)	10.40±31.69	-5.66 (＜.001)
Walking ability (6MWD, m)	Exp. (n=16)	334.38±58.53	403.13±52.50	-8.23 (＜.001)	68.75±33.04
Health related quality of life	Cont. (n=25)	72.54±11.77	72.77±12.48	-0.37 (.709)	0.23±3.04	-9.05 (＜.001)
Health related quality of life	Exp. (n=16)	65.53±10.53	79.79±7.340	-9.99 (＜.001)	14.26±5.71

Exp.=experimental group; Cont.=control group; KASI=Korean Activity Scale/Index; 6MWD=6 minute walk distance;

^†t-tests for mean differences between pretest and posttests within groups,

^‡t-test for mean differences between experimental and control groups.

REFERENCES

1.Baliga RR, Dec GW, Narula J. Practice guidelines for the diagnosis and management of systolic heart failure in low- and middle-income countries. Global Heart. 2013;8(2):141-70. http://dx.doi.org/10.1016/j.gheart.2013.05.002.
Article
2.Alosco ML, Spitznagel MB, Miller L, Raz N, Cohen R, Sweet LH, et al. Depression is associated with reduced physical activity in persons with heart failure. Health Psychology: Official Journal of the Division of Health Psychology. American Psychological Association. 2012;31(6):754-62. http://dx.doi.org/10.1037/a0028711.
3.Dontje ML, van der Wal MH, Stolk RP, Brugemann J, Jaarsma T, Wijtvliet PE, et al. Daily physical activity in stable heart failure patients. The Journal of Cardiovascular Nursing. 2014;29(3):218-26. http://dx.doi.org/10.1097/JCN.0b013e318283ba14.
Article
4.Alahmari AD, Patel AR, Kowlessar BS, Mackay AJ, Singh R, Wedzicha JA, et al. Daily activity during stability and exacerbation of chronic obstructive pulmonary disease. BMC Pulmonary Medicine. 2014;14:98-2466. -14-98.http://dx.doi.org/10.1186/1471-2466-14-98.
Article
PDF
5.Araiza P, Hewes H, Gashetewa C, Vella CA, Burge MR. Efficacy of a pedometer-based physical activity program on parameters of diabetes control in type 2 diabetes mellitus. Metabolism: Clinical and Experimental. 2006;55(10):1382-7. http://dx.doi.org/10.1016/j.metabol.2006.06.009.
6.Conraads VM, Deaton C, Piotrowicz E, Santaularia N, Tierney S, Piepoli MF, et al. Adherence of heart failure patients to exercise: Barriers and possible solutions: A position statement of the study group on exercise training in heart failure of the heart failure association of the european society of cardiology. European Journal of Heart Failure. 2012;14(5):451-8. http://dx.doi.org/10.1093/eurjhf/hfs048.
7.Heo S, Lennie TA, Okoli C, Moser DK. Quality of life in patients with heart failure: Ask the patients. Heart & Lung: The Journal of Critical Care. 2009;38(2):100-8. http://dx.doi.org/10.1016/j.hrtlng.2008.04.002.
Article
8.Juenger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W, et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart (British Cardiac Society). 2002;87(3):235-41. http://dx.doi.org/10.1136/heart.87.3.235.
9.European Association of Cardiovascular Prevention and Rehabilitation Committee for Science Guidelines, EACPR. Corra U, Piepoli MF, Carre F, Heuschmann P, et al. Secondary prevention through cardiac rehabilitation: Physical activity counselling and exercise training: Key components of the position paper from the cardiac rehabilitation section of the european association of cardiovascular prevention and rehabilitation. European Heart Journal. 2010;31(16):1967-74. http://dx.doi.org/10.1093/eurheartj/ehq236.
10.Jolly K, Taylor RS, Lip GY, Davies M, Davis R, Mant J, et al. A randomized trial of the addition of home-based exercise to specialist heart failure nurse care: the birmingham rehabilitation uptake maximisation study for patients with congestive heart failure (BRUM-CHF) study. European Journal of Heart Failure. 2009;11(2):205-13. http://dx.doi.org/10.1093/eurjhf/hfn029.
11.Corvera-Tindel T, Doering LV, Woo MA, Khan S, Dracup K. Effects of a home walking exercise program on functional status and symptoms in heart failure. American Heart Journal. 2004;147(2):339-46. http://dx.doi.org/10.1016/j.ahj.2003.09.007.
Article
12.Gary R, Lee SY. Physical function and quality of life in older women with diastolic heart failure: effects of a progressive walking program on sleep patterns. Progress in Cardiovascular Nursing. 2007;22(2):72-80. http://dx.doi.org/10.1111/j.0889-7204.2007.05375.x.
Article
13.Oka RK, De Marco T, Haskell WL, Botvinick E, Dae MW, Bolen K, et al. Impact of a home-based walking and resistance training program on quality of life in patients with heart failure. The American Journal of Cardiology. 2000;85(3):365-9. http://dx.doi.org/10.1016/S0002-9149(99)00748-1.
14.Dracup K, Evangelista LS, Hamilton MA, Erickson V, Hage A, Moriguchi J, et al. Effects of a home-based exercise program on clinical outcomes in heart failure. American Heart Journal. 2007;154(5):877-83. http://dx.doi.org/10.1016/j.ahj.2007.07.019.
15.Baker G, Mutrie N, Lowry R. Using pedometers as motivational tools: Are goals set in steps more effective than goals set in minutes for increasing walking? International Journal of Health Promotion and Education. 2008;46(1):21-6. http://dx.doi.org/10.1080/14635240.2008.10708123.
Article
16.Evangelista LS, Dracup K, Erickson V, McCarthy WJ, Hamilton MA, Fonarow GC. Validity of pedometers for measuring exercise adherence in heart failure patients. Journal of Cardiac Failure. 2005;11(5):366-71. http://dx.doi.org/10.1016/j.cardfail.2004.10.005.
17.Kang SM. Cardiac rehabilitation of heart failure. Korean Journal of Medicine. 2012;82(6):667-70.
18.Corvera-Tindel T, Doering LV, Gomez T, Dracup K. Predictors of noncompliance to exercise training in heart failure. The Journal of Cardiovascular Nursing. 2004;19(4):269-77. quiz 278-9.http://dx.doi.org/10.1097/00005082-200407000-00006.
19.Duncan K, Pozehl B. Effects of an exercise adherence intervention on outcomes in patients with heart failure. Rehabilitation Nursing: The Official Journal of the Association of Rehabilitation Nurses. 2003;28(4):117-22. http://dx.doi.org/10.1002/j.2048-7940.2003.tb01728.x.
Article
20.Foster C, Hillsdon M, Thorogood M, Kaur A, Wedatilake T. Interventions for promoting physical activity. The Cochrane Database of Systematic Reviews. 2005;1:CD003180http://dx.doi.org/10.1002/14651858.CD003180.pub2.
Article
21.Lee ES, Shin ES, Hwang SY, Chae MJ, Jeong MH. Effects of tailored supportive education on physical, emotional status and quality of life inpatients with congestive heart failure. Korean Journal of Adult Nursing. 2013;25(1):62-73. http://dx.doi.org/10.7475/kjan.2013.25.1.62.
22.Song EK. Effect of a telephone monitoring on self-management & symptom experiences in patients with heart failure. Journal of Korean Academy of Adult Nursing. 2005;17(1):56-67.
23.Kim SM, Lee HJ. Effects of motivational interviewing on disease-related knowledge, depression, self-care, and quality of life in patients with heart failure. Journal of the Korean Gerontological Nursing. 2013;15(2):143-54.
24.Oh JY, Yang YJ, Kim BS, Kang JH. Validity and reliability of Korean version of international physical activity questionnaire (IPAQ) short form. Journal of the Korean Academy on Family Medicine. 2007;28(7):532-41.
25.Feinstein AR, Fisher MB, Pigeon JG. Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure. The American Journal of Cardiology. 1989;64(1):50-5. http://dx.doi.org/10.1016/0002-9149(89)90652-8.
Article
26.Sung JD, On YK, Chae IH, Kim HS, Sohn DW, Oh BH, et al. Development of korean activity scale/index (KASI). Korean Circulation Journal. 2000;30(8):1004-9. http://dx.doi.org/10.4070/kcj.2000.30.8.1004.
27.Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, et al. The 6-minute walk: A new measure of exercise capacity in patients with chronic heart failure. Canadian Medical Association Journal. 1985;132(8):919-23.
28.Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas city cardiomyopathy questionnaire: a new health status measure for heart failure. Journal of the American College of Cardiology. 2000;35(5):1245-55. http://dx.doi.org/10.1016/S0735-1097(00)00531-3.
29.Lee HJ, Kim SM, Lim YJ, Ahn JJ, Kim YS, Park HK. Comparison of characteristics of drop-outs from study participation between intervention and comparison groups. Journal of the Korean Gerontological Nursing. 2012;14(2):110-7.
30.Mun CI, Rhim YT. Psychological and physiological variables appreciation for adherence of exercise. Journal of Coaching Development. 2007;9(4):57-69.

Figure & Data

References

Citations

Citations to this article as recorded by

A Case Report on the Improvement of Dyspnea and Edema Caused by Heart Failure Through a Complex Korean Medicine Treatment
Jumin Kim, Hyeryun Lee, Hyungsun Jun, Dasol Park, Jungtae Leem
The Journal of Internal Korean Medicine.2025; 46(1): 172. CrossRef
Exercise-based cardiac rehabilitation for adults with heart failure
Cal Molloy, Linda Long, Ify R Mordi, Charlene Bridges, Viral A Sagar, Edward J Davies, Andrew JS Coats, Hasnain Dalal, Karen Rees, Sally J Singh, Rod S Taylor
Cochrane Database of Systematic Reviews.2024;[Epub] CrossRef
Home-based versus centre-based cardiac rehabilitation
Sinead TJ McDonagh, Hasnain Dalal, Sarah Moore, Christopher E Clark, Sarah G Dean, Kate Jolly, Aynsley Cowie, Jannat Afzal, Rod S Taylor
Cochrane Database of Systematic Reviews.2023;[Epub] CrossRef
The Effects of Exercise-Based Interventions on Fluid Overload Symptoms in Patients with Heart Failure: A Systematic Review and Meta-Analysis
Mei Rosemary Fu, Yuan Li, Catherine Conway, Alessandra Masone, Jinbo Fang, Christopher Lee
Biomedicines.2022; 10(5): 1111. CrossRef
Effects of Smartphone-Based Compensatory Cognitive Training and Physical Activity on Cognition, Depression, and Self-Esteem in Women with Subjective Cognitive Decline
Yanghee Pang, Oksoo Kim
Brain Sciences.2021; 11(8): 1029. CrossRef

Cite

CITE

export

Copy Download

Format
XML Download

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

The Effects of Reinforced Walking Exercise on Dyspnea-fatigue Symptoms, Daily Activities, Walking Ability, and Health related Quality of Life in Heart Failure Patients

Korean J Adult Nurs. 2016;28(3):266-278. Published online June 30, 2016

DOI: https://doi.org/10.7475/kjan.2016.28.3.266

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

The Effects of Reinforced Walking Exercise on Dyspnea-fatigue Symptoms, Daily Activities, Walking Ability, and Health related Quality of Life in Heart Failure Patients

Korean J Adult Nurs. 2016;28(3):266-278. Published online June 30, 2016

DOI: https://doi.org/10.7475/kjan.2016.28.3.266

Figure

The Effects of Reinforced Walking Exercise on Dyspnea-fatigue Symptoms, Daily Activities, Walking Ability, and Health related Quality of Life in Heart Failure Patients

Figure 1. Flow chart of data collection.

Figure 1.

The Effects of Reinforced Walking Exercise on Dyspnea-fatigue Symptoms, Daily Activities, Walking Ability, and Health related Quality of Life in Heart Failure Patients

Table 1.

Reinforced Walking Exercise Program

Categories	Contents	Time
1) Preparation	(1) Perform physical assessment (Vital sign & SpO2)	10 min
	(2) Instruct how to use pedometer: Mode & Reset
	(3) Offer exercise diary & teach how to use the diary: Recording number of steps, duration of exercise, weekly frequency, heart rate, and dyspnea/fatigue borg scale
2) Goal setting	(1) Perform walking exercise using the pedometer	5 min
	(2) Start from 5,000 steps & 10% increase/week
	Start from 1 day/week → 5 days/week
	1st week: 5,000 steps & 1 day/week
	2nd week: 6,000 steps & 2 days/week
	3rd week: 7,000 steps & 3 days/week
	4th week: 8,000 steps & 4 days/week
	5th week: 9,000 steps & 5 days/week
	6th week: 10,000 steps & 5 days/week
	7~12th week: maintain 10,000↑steps & 5 days/week
	(3) Maintain symptom of dyspnea/fatigue based on borg scale 12~13 point, maximum heart rate 60~70%
3) Feedback	(1) Check pedometer data and incomplete data	5 min
	(2) Mutually set a weekly goal of walking.
	(3) Reinforce maintenance of walking exercise
	→ through telephone call:
	1st~6th week=once a week
	7~12th week=every other week
	→ by text message: 2 days/week

Table 2.

Characteristics and Homogeneity Test between Control and Experimental Groups (N=41)

Characteristics		Categories	Total	Control (n=25)	Exp. (n=16)	x² or t (p)
Characteristics		Categories	n (%) or M±SD	D n (%) or M±SD	n (%) or M±SD	x² or t (p)
Age (year) (range 40~77)		＜65	30 (73.2)	17 (68.0)	13 (81.3)	0.87 (.287)^§
		≥65	11 (26.8)	8 (32.0)	3 (18.8)	-0.86 (.393)
			58.02±12.04	56.72±14.38	60.06±6.97
Gender		Male	30 (73.2)	17 (68.0)	13 (81.3)	0.87 (.478)^§
Gender		Female	11 (26.8)	8 (32.0)	3 (18.8)
Spouse		No	2 (4.9)	0 (0.0)	2 (12.5)	3.29 (.146)^§
Spouse		Yes	39 (95.1)	25 (100.0)	14 (87.5)
Level of education		≤Junior high school	9 (22.0)	7 (28.0)	2 (12.5)	6.61 (.085)
		High school	13 (31.7)	5 (20.0)	8 (50.0)
		≥College	19 (46.3)	13 (52.0)	6 (37.5)
Regular exercise		No	41 (100.0)	25 (100.0)	16 (100.0)
Monthly household income (10,000 won)		＜100	4 (9.8)	2 (8.0)	2 (12.5)	0.32 (.854)
		100~199	7 (17.1)	4 (16.0)	3 (18.8)
		≥200	30 (73.2)	19 (76.0)	11 (68.8)
Left ventricular ejection fraction (%)			31.15±6.92	31.88±6.98	30.00±6.88	0.85 (.403)
NYHA class		II	36 (87.8)	22 (88.8)	14 (87.5)	0.01 (＞.999)^§
NYHA class		III	5 (12.2)	3 (12.0)	2 (12.5)
Comorbidity		No	16 (39.0)	11 (44.0)	5 (31.3)	0.67 (.519)^§
		Yes^†	25 (61.0)	14 (56.0)	11 (68.8)
		Hypertension	25 (100.0)	14 (56.0)	11 (44.0)
		Diabetes mellitus	6 (24.0)	2 (8.0)	4 (16.0)
		Etc.^‡	7 (28.0)	3 (12.0)	4 (16.0)
Medication	Beta-blocker	Yes	35 (85.4)	21 (84.0)	14 (87.5)	0.10 (＞.999)^§
	Beta-blocker	No	6 (14.6)	4 (16.0)	2 (12.5)
	ACE inhibitor	Yes	29 (70.7)	17 (68.0)	12 (75.0)	0.23 (.734)^§
	ACE inhibitor	No	12 (29.3)	8 (32.0)	4 (25.0)
	Diuretics	Yes	31 (75.6)	19 (76.0)	12 (75.0)	0.01 (＞.999)^§
	Diuretics	No	10 (24.4)	6 (24.0)	4 (25.0)
Physical activity (MET-minutes/week)		Inactive	26 (63.4)	18 (72.0)	8 (50.0)	3.11 (.211)
		Minimally active	11 (26.8)	6 (24.0)	3 (31.3)
		HEPA	4 (9.8)	1 (2.4)	3 (18.8)

Exp.=experimental group; NYHA=New York Heart Association; HEPA=Health enhancing physical activity;

^†Multiple responses;

^‡Liver disease, osteoporosis, angina pectoris, pulmonary disease;

^§Fisher's exact test.

Table 3.

Levels of Dyspnea-fatigue Symptoms, Daily Activities, Walking Ability and Health related QoL and Homogeneity Test (N=41)

Characteristics	Total	Cont. (n=25)		Exp. (n=16)		t (p)
Characteristics	M±SD	M±SD	Z^† (p)	M±SD	Z^† (p)	t (p)
Dyspnea-fatigue symptoms	5.90±1.88	6.20±1.78	0.967 (.307)	5.44±2.00	.943 (.336)	1.28 (.210)
Daily activities (KASI)	34.76±11.75	35.02±11.57	0.646 (.798)	34.35±12.40	.817 (.517)	0.18 (.861)
Walking ability (6MWD; m)	337.32±71.03	339.20±79.11	1.019 (.251)	334.38±58.53	.388 (.998)	0.21 (.835)
HRQoL	69.80±11.69	72.54±11.77	1.052 (.219)	65.53±10.53	.823 (.508)	1.94 (.060)

Exp.=experimental group; Cont.=control group; KASI=Korean Activity Scale/Index; 6MWD=Six-minute walk distance; HRQoL=Health related quality of life.

^†Kolmogorov-Smirnove test.

Table 4.

Walking Compliance and Levels of Physical Activity in Experimental Group (N=16)

Characteristics	Pretest	Posttest	t (p)
Characteristics	n (%) or M±SD	n (%) or M±SD	t (p)
Walking compliance (MET-minute/week)^†
＜825	15 (93.8)	0 (0.0)
≥825	1 (6.3)	16 (100.0)
Physical activity^‡	2110.50±1693.79	3611.25±2513.51	3.45 (.041)
Inactive	8 (50.0)	0 (0.0)
Minimally active	5 (31.3)	12 (75.0)
HEPA	3 (18.8)	4 (25.0)

MET=metabolic equivalent task; HEPA=health enhancing physical activity;

^†Walking 3.3 MET × 50 min/day × 5 times/week=825 MET-min/week;

^‡International Physical Activity Questionnaire scoring protocol (MET-min/week).

Table 5.

Effects of Reinforced Walking Exercise Program on Patients Outcomes (N=41)

Variables	Groups	Pretest	Posttest	t (p)^†	Mean differences	t (p)
Variables	Groups	M±SD	M±SD	t (p)^†	Mean differences	t (p)
Global perceived improvement in dyspnea-fatigue	Cont. (n=25)	-	4.08±0.57			8.63
Global perceived improvement in dyspnea-fatigue	Exp. (n=16)	-	2.56±0.51			(＜.001)^‡
Daily activities (KASI)	Cont. (n=25)	35.02±11.57	35.38±12.00	0.60 (.553)	0.36±3.02	-4.92 (＜.001)
Daily activities (KASI)	Exp. (n=16)	34.35±12.40	39.80±13.03	6.16 (＜.001)	5.45±3.53
Walking ability (6MWD, m)	Cont. (n=25)	339.20±79.11	349.60±78.87	-1.64 (.114)	10.40±31.69	-5.66 (＜.001)
Walking ability (6MWD, m)	Exp. (n=16)	334.38±58.53	403.13±52.50	-8.23 (＜.001)	68.75±33.04
Health related quality of life	Cont. (n=25)	72.54±11.77	72.77±12.48	-0.37 (.709)	0.23±3.04	-9.05 (＜.001)
Health related quality of life	Exp. (n=16)	65.53±10.53	79.79±7.340	-9.99 (＜.001)	14.26±5.71

Exp.=experimental group; Cont.=control group; KASI=Korean Activity Scale/Index; 6MWD=6 minute walk distance;

^†t-tests for mean differences between pretest and posttests within groups,

^‡t-test for mean differences between experimental and control groups.

Table 1. Reinforced Walking Exercise Program

Table 2. Characteristics and Homogeneity Test between Control and Experimental Groups (N=41)

Exp.=experimental group; NYHA=New York Heart Association; HEPA=Health enhancing physical activity;

†

Multiple responses;

‡

Liver disease, osteoporosis, angina pectoris, pulmonary disease;

Fisher's exact test.

Table 3. Levels of Dyspnea-fatigue Symptoms, Daily Activities, Walking Ability and Health related QoL and Homogeneity Test (N=41)

Exp.=experimental group; Cont.=control group; KASI=Korean Activity Scale/Index; 6MWD=Six-minute walk distance; HRQoL=Health related quality of life.

†

Kolmogorov-Smirnove test.

Table 4. Walking Compliance and Levels of Physical Activity in Experimental Group (N=16)

MET=metabolic equivalent task; HEPA=health enhancing physical activity;

†

Walking 3.3 MET × 50 min/day × 5 times/week=825 MET-min/week;

‡

International Physical Activity Questionnaire scoring protocol (MET-min/week).

Table 5. Effects of Reinforced Walking Exercise Program on Patients Outcomes (N=41)

Exp.=experimental group; Cont.=control group; KASI=Korean Activity Scale/Index; 6MWD=6 minute walk distance;

†

t-tests for mean differences between pretest and posttests within groups,

‡

t-test for mean differences between experimental and control groups.

Articles

Page Path

The Effects of Reinforced Walking Exercise on Dyspnea-fatigue Symptoms, Daily Activities, Walking Ability, and Health related Quality of Life in Heart Failure Patients

Full Article

Abstract

REFERENCES

Figure & Data

References

Citations

CITE

Download Citation

Format:

Include:

Figure

Figure 1.

Table 1.

Table 2.

Table 3.

Table 4.

Table 5.

ABOUT

BROWSE ARTICLES

EDITORIAL POLICY

FOR CONTRIBUTORS